Search for Topics:
Title/Keyword
Journal
Submission Status
Category
 
 
Topics
Advances in Anti-Cancer Drugs: 2nd Edition
Submit your Manuscript Propose a Topic

Topic Menu

► Topic Menu

Topic Editors

Department of Biological Sciences, The Border Biomedical Research Center (BBRC), The University of Texas at El Paso, El Paso, TX 79968, USA
Department of Biological Sciences, The Border Biomedical Research Center (BBRC), The University of Texas At El Paso, El Paso, TX 79968, USA
Dr. Blanca E. Ruiz-Medina
Departamento de Biología Celular y del Desarrollo, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, México City, Mexico
Dr. Patricia Talamás-Rohana
Department of Infectomics and Molecular Pathogenesis, Centro de Investigación y de Estudios Avanzados (CINVESTAV), Instituto Politecnico Nacional, Mexico City, Mexico
Laboratory of Medicinal Chemistry, Department of Biology, University of Massachusetts, Amherst, MA 01003-9297, USA
share announcement

Advances in Anti-Cancer Drugs: 2nd Edition

Abstract submission deadline
closed (31 May 2025)
Manuscript submission deadline
31 August 2025
Viewed by
1155

Topic Information

Dear Colleagues,

This Topic is the second edition of the collection “Advances in Anti-Cancer Drugs”, available at https://www.mdpi.com/topics/AIACD.

We hope this message finds you well. As large quantities of novel synthetic and natural molecules continue to be generated or discovered, it is challenging to identify and characterize therapeutic agents with effective anti-cancer activity.

The aim of this particular Topic, "Advances in Anti-Cancer Drugs”, is to collect a group of publications focused on novel chemical compounds with cytotoxic activity against cancer cells, whether in vitro, in vivo, or both, particularly including articles that present novel biomarkers and target proteins with potential therapeutic properties. In addition, submissions are encouraged for studies on drug repurposing, including approved, discontinued, and shelved drugs with anti-cancer activity. Moreover, immunotherapy, electrochemotherapy, gene therapy, and phytomedicine studies are highly welcome.

The submitted manuscripts should include the partial mechanism used for novel compounds and therapeutic strategies. Information on the potential mechanism of action should be included. This Topic provides a suitable platform to disseminate anti-cancer discoveries at the bench and the bedside. Thus, we are delighted to invite you to participate in this excellent opportunity to publish your manuscript in our journal.

Dr. Armando Varela-Ramirez
Dr. Elisa Robles-Escajeda
Dr. Blanca E. Ruiz-Medina
Dr. Patricia Talamás-Rohana
Dr. Rachid Skouta
Topic Editors

Keywords

  • anticancer
  • antiproliferation
  • apoptosis
  • biomarkers
  • cell cycle
  • cell signaling
  • drug discovery
  • immunotherapy
  • gene therapy
  • phytomedicine

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Cancers
cancers 		4.4 8.8 2009 20.3 Days CHF 2900 Submit
Medicines
medicines 		- - 2014 45 Days CHF 1400 Submit
Medical Sciences
medsci 		4.4 8.7 2013 24.3 Days CHF 1600 Submit
Cells
cells 		5.2 10.5 2012 16 Days CHF 2700 Submit
Pharmaceuticals
pharmaceuticals 		4.8 7.7 2004 14 Days CHF 2900 Submit
Biology
biology 		3.5 7.4 2012 17.4 Days CHF 2700 Submit
Biologics
biologics 		- 7.2 2021 23.5 Days CHF 1200 Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

  1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
  2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
  3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
  4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
  5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (2 papers)

Order results
Result details
Journals
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
21 pages, 3781 KiB  
Article
Ginsenoside Rg3 Adjunctively Increases the Efficacy of Gefitinib Against NSCLC by Regulating EGFR Copy Number
by Xinyi Lv, Yuehan Song, Tianhua Liu, Dingdan Zhang, Xinpeng Ye, Qingqing Wang, Rongrong Li, Jiayi Chen, Shujing Zhang, Xue Yu and Chunying Hou
Pharmaceuticals 2025, 18(7), 1077; https://doi.org/10.3390/ph18071077 - 21 Jul 2025
Abstract
Background: Lung cancer has the highest morbidity and mortality of all tumors, and the development of TKI drugs targeting EGFR activating mutations has brought lung cancer treatment into the targeted era. In view of their low efficacy and susceptibility to drug resistance, [...] Read more.
Background: Lung cancer has the highest morbidity and mortality of all tumors, and the development of TKI drugs targeting EGFR activating mutations has brought lung cancer treatment into the targeted era. In view of their low efficacy and susceptibility to drug resistance, there is an urgent need to find strategies to increase their efficacy and reduce the incidence of drug resistance. Methods: In this study, we examined the distribution and probability of EGFR mutations in non-small cell lung cancer patients in the cBioPortal database and compared the survival prognosis of patients with normal and abnormal EGFR, NSCLC patients treated with and without TKI, and NSCLC patients with different EGFR gene copy numbers. We established a mouse lung cancer model and examined the histomorphological characteristics of lung tissues via hematoxylin and eosin staining. Additionally, changes in the copy number of the EGFR gene and its protein expression levels were detected using RT-qPCR and Western blotting. Furthermore, we quantified the concentration of the EGFR protein using ELISA. Results: We found no significant advantage of EGFR-TKI therapy over first-line chemotherapeutic agents in patients with EGFR-abnormal NSCLC. The reason for this may be related to the abnormal EGFR gene copy number; the higher the copy number increases, the worse the survival prognosis of the patients. In molecular biology experiments, we demonstrated that ginsenoside Rg3 down-regulated the copy number of 18, 19, 20, and 21 exons and protein expression of EGFR in lung adenocarcinoma cells. The results of in vivo pharmacodynamic assays confirmed that sequential administration of ginsenoside Rg3 with TKI drugs could achieve a gainful complementary effect. Conclusions: Ginsenoside Rg3 down-regulates the copy number of EGFR important exons in EGFR-mutant cells of lung adenocarcinoma and reduces EGFR protein expression, thus providing a high gainful complementary effect in combination with EGFR-TKI. Full article
(This article belongs to the Topic Advances in Anti-Cancer Drugs: 2nd Edition)
►▼ Show Figures

Figure 1

21 pages, 1210 KiB  
Article
Taurine-Based Hybrid Drugs as Potential Anticancer Therapeutic Agents: In Vitro, In Vivo Evaluations
by Saltanat Nakypova, Andrey Smolobochkin, Tanzilya Rizbayeva, Rakhymzhan Turmanov, Almir Gazizov, Nurgali Akylbekov, Rakhmetulla Zhapparbergenov, Roza Narmanova, Saltanat Ibadullayeva, Alena Zalaltdinova, Marat Syzdykbayev, Julia Voronina, Anna Lyubina, Alexandra Voloshina, Elena Klimanova, Tatiana Sashenkova, Denis Mishchenko and Alexander Burilov
Pharmaceuticals 2025, 18(7), 1056; https://doi.org/10.3390/ph18071056 - 18 Jul 2025
Viewed by 153
Abstract
Background/Objectives: The development of antitumor agents possessing low toxicity against non-cancerous cells is still a challenge in medicinal chemistry. In this paper, we report the antitumor activity of “hybrid structures” derived from the amino acid taurine. We have synthesized 26 compounds, structures [...] Read more.
Background/Objectives: The development of antitumor agents possessing low toxicity against non-cancerous cells is still a challenge in medicinal chemistry. In this paper, we report the antitumor activity of “hybrid structures” derived from the amino acid taurine. We have synthesized 26 compounds, structures of which were confirmed using NMR, X-ray diffractometry, and other techniques. Cytotoxicity of the obtained compounds has been evaluated using three human cancer cell lines. Pyrrolidine 4p has exhibited the strongest antiproliferative activity against HL-60 cells with an IC50 of 76.7 μM, while IC50 against normal cells was 176.3 μM. Water-soluble derivatives of taurine have been tested for antileukemia activity in mice of the BDF1 line. Compound 4p has been identified as the leading compound, which increases the mean survival time of mice from 40 to 100% as compared to the control group. Together, these results prove that taurine-based hybrid structures can be a promising scaffold for the discovery of potential antiproliferative agents. Full article
(This article belongs to the Topic Advances in Anti-Cancer Drugs: 2nd Edition)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop